S-CHOice® 2G
CHO Cell Line Technology with S-CHOice® Platform
S-CHOice® is our proprietary CHO cell line development platform based on GS knock-out technology. The platform delivers high titers for a wide range of modalities, including monoclonal antibodies, and shows strong cell viability in fed-batch cell culture conditions. Learn more about our Process Development and Analytical Development offerings.
-
-
S-AfuCHO™
S-AfuCHO™
-
An upgraded S-CHOice® cell line to produce enhanced ADCC* activity antibodies
*ADCC: Antibody Dependent Cellular Cytotoxicity
-
-
-
Samsung Biologics Transposase
Samsung Biologics Transposase
- Samsung's Transposon System that enables high titers
-
End-to-End CDMO Cell Line Development Workflow
Random Integration
3 months
- Transfection
- Plating(mini/bulk pool)
- Primary Screening
- Single CellCloning
- Secondary Screening
- Stability
Semi Targeted Integration (Transposase)
2 months
Random Integration
3 months
- Transfection
- Plating(mini/bulk pool)
- Primary Screening
- Single CellCloning
- Secondary Screening
- Stability
Semi Targeted Integration (Transposase)
2 months
Integrated In-house Cell Line Development Capabilities
-
-
Beacon®
Beacon®
- Beacon® enables automated high-throughput cell imaging and in-channel assays for rapid selection of top-producing clones. This single cell cloning platform accelerates cell line development by enabling real-time assessment of productivity and stability.
-
-
-
C.SIGHT™
C.SIGHT™
- The C.SIGHT™ system offers a gentle, imaging-based method for single-cell sorting into multi-well formats. It enables cost-effective clone isolation with high accuracy and viability. These tools support efficient stable cell line generation and contribute to faster project timelines across Non-GMP / CGMP Manufacturing.
-
-
-
Vector
Vector
- Alongside the advantages of client's data security and IP protection, Samsung Biologics' in-house vector construction capabilities enable smooth operations of CDO services.
-
-
-
MCB
MCB
- Samsung Biologics' in-house capabilities to produce and bank MCBs enables, not only smooth transition from cell line development stability to MCB manufacturing, but also into GMP productions.
-
Related Content
S-CHOice®2G
Accelerated Cell Line
Development for IND Submission
Samsung Biologics provides streamlined, high-quality cell line development services to help you achieve faster IND/IMPD submissions. Our extensive expertise in Biopharma Development and regulatory support ensures rapid progress through early-stage development while minimizing cost and timeline risks.